The series is stated in the current share scale after splits; dividends are not included in the price
Regeneron is a biotechnology company whose revenue long rested on a single eye medicine.
The base is a medicine for age-related macular degeneration, injected into the eye. It supplied most of the revenue for years and still does, but faces biosimilars and a competitor requiring less frequent injections. Defending that position means moving to a higher-dose formulation with longer intervals.
The second pillar is an immunology medicine developed with Sanofi for asthma, dermatitis and chronic obstructive pulmonary disease. It grows quickly and is gradually replacing ophthalmology as the main income source.
The company's distinguishing feature is its own antibody discovery platform, recognised in the industry and licensed to partners. The risks are the usual ones: trial results, regulatory decisions, price pressure. The company pays no dividend, directing cash into research and buybacks.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Share count is a period average, so market cap is approximate.
Regeneron Pharmaceuticals, Inc. (REGN) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Regeneron Pharmaceuticals, Inc. (REGN) on November 2, 2026 is 963.11 $, +3.80 % on the day. Over the past year the price changed by +38.15 %. The P/E ratio is 22.69, which is below the sector median (24.61). Market capitalization is 98.22 billion $, rank 9 among 380 stocks of the same industry with a known capitalization.
Regeneron Pharmaceuticals, Inc. trades on Nasdaq under the ticker REGN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks REGN has traded between 564.00 $ and 859.34 $. As of 2 November 2026 the price stood 78.67 % of the way from the 52-week low to the high.
Over one year REGN shares rose 38.15 %; over six months they rose 6.75 %. Volatility over 90 days is 29.05 %. Dividends are not included: this is price change only, as of 2 November 2026.
REGN trades at a price-to-earnings ratio of 22.7, below the sector median of 24.6. Price to sales is 6.3, above the sector median of 3.6. Price to book is 3.1, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Regeneron Pharmaceuticals, Inc. reported revenue of 15.5B $ and net income of 4.3B $ over the last four quarters. Net margin is 27.86 %. Revenue changed by +9.29 % year over year. Earnings per share are 40.41 $. Market capitalisation is 98.2B $.
REGN has a return on equity of 13.65 %, above the sector median of −40.58 %. Return on assets is 10.37 %, above the sector median of −30.08 %. Operating margin is 24.74 %, above the sector median of −20.96 %.
Regeneron Pharmaceuticals, Inc. pays dividends quarterly: 3.70 $ per share over the past twelve months, a yield of 0.40 %. The latest payment was 0.94 $, with an ex-dividend date of 18 August 2026.
